top of page

Сomparative study

PJSC “SPC “Diaproph-Med” in accordance with the requirements of the international quality management standard ISO13485, conducted a comparative study of amino acid sequences of recombinant antigens SARS-CoV-2 of its own production and proteins of Indian isolate SARS-CoV-2 "DELTA" (B.1.617.2) according to the European Center for Disease Prevention and Control (ECDC) risk assessment report 1.


The genome of the Indian strain DELTA SARS-CoV-2 does not contain large deletions in diagnostically important sites, but has a large number of point substitutions (mutations) in the gene responsible for the synthesis of surface protein SPIKE.


Thus, the nucleocapsid protein (NP) SARS-CoV-2 of own production and the nucleocapsid protein (NP) SARS-CoV-2 "DELTA" B.1.617.2 variant GenBank accession No. QWP92477.1 has a match of 98.8%.

Surface protein (SPIKE) SARS-CoV-2 of own production and Surface protein (SPIKE) SARS-CoV-2 SPIKE "DELTA" B.1.617.2 variant GenBank accession No. QWP92470.1 has a match of 99.3%.

Membrane protein (M) SARS-CoV-2 of own production and Membrane protein (M) SARS-CoV-2 «DELTA» B.1.617.2 variant GenBank accession No. QUX81285.1 has a match of 99.1%.

Shell protein (E) SARS-CoV-2 of own production and Shell protein (E) SARS-CoV-2 "DELTA" B.1.617.2 variant GenBank accession No. QUX81284.1 has a match of 100%.


The comparison shows the absence of a significant threat of reducing the diagnostic sensitivity of test systems manufactured by PJSC “SPC “Diaproph-Med” for the detection of coronavirus disease due to mutations in variants of the strain "DELTA" (B.1.617.2) SARSCoV-2.

Introduction of multi-target test systems such as DIA®-SARS-CoV-2-NP-S-IgM for qualitative detection of IgM antibodies to nucleoprotein (nucleocapsid antigen, NP) and surface (spike-protein, S) antigens of coronavirus SARS-CoV -2, DIA®-SARS-CoV-2-different for differential detection of antibodies to all structural proteins of the virus - NP, S, M and E provides a tool for diagnostic laboratories for in-depth research in the face of new mutations in the virus.


Specialists of PJSC “SPC “Diaproph-Med” are constantly monitoring SARS-CoV-2 mutations and the emergence of new variants of the virus in order to improve the design of test systems to ensure maximum sensitivity and specificity.


17 views0 comments

Comments


Commenting has been turned off.
bottom of page